Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 826, Issue , 1997, Pages 317-322

  Schneider, Lon S ^a,b,c   Farlow, Martin ^d  

^a Department of Psychiatry ^*  (United States)

^b SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; TACRINE;

ADULT; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030723050     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb48482.x     Document Type: Conference Paper

References (17)

1. HEFTI, F. & L. S. SCHNEIDER. 1989. Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease. Psychiatr. Dev. 4: 297-315.
2. KNAPP, M. J., D. S. KNOPMAN, P. R. SOLOMON, W. W. PENDLEBURY, C. S. DAVIS & S. I. GRACON, for the Tacrine Study Group. 1994. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271: 985-991.
3. EAGGER, S. A., R. LEVY & B. J. SAHAKIAN. 1991. Tacrine in Alzheimer's disease. Lancet 337: 989-992.
4. FARLOW, M., S. I. GRACON, L. A. HERSHEY, K. W. LEWIS, C. H. SADOWSKY & J. DOLAN-URENO. 1992. A 12-week, double-blind, placebo-controlled, parallel-group study of tacrine in patient with probable Alzheimer's disease. JAMA 268: 2523-2529.
5. DAVIS, K. L., L. J. THAL, E. GAMZU, C. S. DAVIS, R. F. WOOLSON, S. I. GRACON, D. A. DRACHMAN, L. S. SCHNEIDER, P. J. WHITEHOUSE, T. M. HOOVER, J. C. MORRIS, C. H. KAWAS, D. S. KNOPMAN, N. L. EARL, V. KUMAR & R. S. DOODY. 1992. Tacrine in patients with Alzheimer's disease: A double-blind, placebo-controlled multicenter study. N. Engl. J. Med. 327: 1253-1259.
6. SIMPKINS, J. W., M. SINGH & J. BISHOP. 1994. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol. Aging 15(Suppl. 2): S195-S197.
7. PAGANINI-HILL, A. & V. W. HENDERSON. 1994. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140: 256-261.
8. TANG, M. X., D. JACOBS, Y. STERN et al. 1996. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432.
9. SCHNEIDER, L. S., M. R. FARLOW, V. W. HENDERSON & J. M. POGODA. 1996. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 46: 1580-1584.
10. BELCHETZ, P. E. 1994. Hormonal treatment of postmenopausal women. N. Engl. J. Med. 330: 1062-1071.
11. LUINE, V. N., R. KHYLCHEVSKAYA & B. S. MCEWEN. 1975. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 86: 293-306.
12. JOSEFSSON, E., A. TARKOWSKI & H. CARLSTEN. 1992 Anti-inflammatory properties of estrogen. Cellular Immunology 142: 67-78.
13. SCREPANTI, I., A. SANTONI, A. GULINO, R. B. HERBERMAN & L. FRATI. 1987. Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol. 106: 191-202.
14. AISEN, P. S. & K. L. DAVIS. 1994. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am. J. Psychiatry 151: 1105-1113.
15. POIRIER, J., J. DAVIGNON, D. BOUTHILLIER et al. 1993. Apolipoprotein E polymorphisms and Alzheimer's disease. Lancet 342: 697-699.
16. SHERWIN, B. B. & M. M. GELFAND. 1989. A prospective one-year study of estrogen and progestin in postmenopausal women: Effects on clinical symptoms and lipoprotein lipids. Obstet. Gynecol. 73: 759-766.
17. SCHNEIDER, L. S., M. FARLOW, J. POGODA & J. POIRIER. 1997. Interaction of estrogen replacement therapy and apolipoprotein E genotype status on response to cholinesterase inhibitor therapy in Alzheimer's disease. In The Proceedings of the Fifth International Conference on Alzheimer's Disease and Related Disorders. K. Iqbal, B. Winblad & H. Wisniewski, Eds.: 655-659. John Wiley & Sons. England.